|MDACC Study No:||2012-0707 (clinicaltrials.gov NCT No: NCT01578707)|
|Title:||A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|
|Principal Investigator:||Susan O'Brien|
|Treatment Agent:||Ibrutinib; Ofatumumab|
|Study Description:||The goal of this clinical research study is to learn if ibrutinib, also known |
as PCI-32765, can help control the disease when compared to ofatumumab in
patients with CLL or SLL. Researchers also want to learn about the safety of
ibrutinib and how long it stays in the blood.
Ibrutinib is designed to block a protein in cancer cells that may kill or stop
them from growing.
Ofatumumab is designed to bind to the surface of a type of white blood cells.
This may cause cancer cells that come from these white blood cells to die.